Literature DB >> 25394967

[Value of core needle biopsy in preoperative diagnostics of soft tissue tumors: possibilities and limitations].

A Agaimy1.   

Abstract

The differential diagnosis of soft tissue swellings encompasses a variety of benign, intermediate, low-grade malignant and high-grade neoplastic lesions in addition to tumor-like reactive processes. As treatment of these heterogeneous conditions varies greatly from conservative observation and simple local excision up to extensive radical surgical resection, treatment decisions are based mainly on a precise preoperative histological diagnosis on limited biopsy material. Even for clinically unequivocal sarcomas, the importance of the preoperative histological diagnosis has been increasingly emphasized as different therapeutic regimens have been established for different sarcoma types and the indications for preoperative treatment is influenced by the tumor grade and by the entity itself. Other factors positively influencing the increasing use of core needle biopsy for preoperative tumor diagnosis in soft tissue pathology are the availability of modern high-resolution imaging modalities as well as the establishment of several new second generation immunohistochemical markers and the discovery of entity-specific translocations detected by fluorescence in situ hybridization (FISH) in several sarcoma subtypes. In this review it will be shown that a targeted approach for processing core needle biopsies oriented towards the characteristic topographical, demographic, cytomorphological and architectural features of soft tissue lesions facilitates a precise diagnosis of soft tissue neoplasms in most cases. However, profound knowledge of the different aspects of soft tissue tumor diagnostics and familiarity with the frequent as well as the less common and rare tumor entities and variants is a prerequisite for appropriate interpretation of core needle biopsy findings and for selecting a limited but well-suited marker panel. The utilization of modern immunohistochemistry and/or FISH methods is highly useful for establishing the diagnosis of rare and unusual neoplasms in core needle biopsies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394967     DOI: 10.1007/s00292-014-2010-3

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  34 in total

Review 1.  Musculoskeletal neoplasms: biopsy and intervention.

Authors:  Ambrose J Huang; Susan V Kattapuram
Journal:  Radiol Clin North Am       Date:  2011-11       Impact factor: 2.303

2.  Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies.

Authors:  P Mhawech-Fauceglia; F Herrmann; R Penetrante; A Beck; S Sait; A M Block; K Odunsi; J Fisher; L Balos; R T Cheney
Journal:  Histopathology       Date:  2006-12       Impact factor: 5.087

3.  TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

Authors:  Jefferson Terry; Tsuyoshi Saito; Subbaya Subramanian; Cindy Ruttan; Cristina R Antonescu; John R Goldblum; Erinn Downs-Kelly; Christopher L Corless; Brian P Rubin; Matt van de Rijn; Marc Ladanyi; Torsten O Nielsen
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

4.  Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma.

Authors:  Elsa Arbajian; Florian Puls; Linda Magnusson; Khin Thway; Cyril Fisher; Vaiyapuri P Sumathi; Johnbosco Tayebwa; Karolin H Nord; Lars-Gunnar Kindblom; Fredrik Mertens
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

5.  Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases.

Authors:  Thomas Mentzel; Gabriele Palmedo; Cornelius Kuhnen
Journal:  Mod Pathol       Date:  2010-03-12       Impact factor: 7.842

6.  MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre-Garau; Louis Guillou; Gonzague de Pinieux; Philippe Terrier; Réal Lagacé; Alain Aurias; Isabelle Hostein; Jean Michel Coindre
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

Review 7.  Grading of soft tissue sarcomas: review and update.

Authors:  Jean-Michel Coindre
Journal:  Arch Pathol Lab Med       Date:  2006-10       Impact factor: 5.534

8.  Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.

Authors:  Sarah Barthelmeß; Helene Geddert; Carsten Boltze; Evgeny A Moskalev; Matthias Bieg; Horia Sirbu; Benedikt Brors; Stefan Wiemann; Arndt Hartmann; Abbas Agaimy; Florian Haller
Journal:  Am J Pathol       Date:  2014-02-08       Impact factor: 4.307

9.  Neoadjuvant treatment of soft tissue sarcoma.

Authors:  Daniela Greto; Lorenzo Livi; Calogero Saieva; Pierluigi Bonomo; Icro Meattini; Mauro Loi; Lucia Di Brina; Giovanni Beltrami; Domenico Campanacci; Guido Scoccianti; Rodolfo Capanna; Monica Mangoni; Fabiola Paiar; Alessandro Franchi; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

10.  Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.

Authors:  Juliann Chmielecki; Aimee M Crago; Mara Rosenberg; Rachael O'Connor; Sarah R Walker; Lauren Ambrogio; Daniel Auclair; Aaron McKenna; Michael C Heinrich; David A Frank; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-01-13       Impact factor: 38.330

View more
  1 in total

1.  Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma.

Authors:  J Kiefer; M Mutschler; Ph Kurz; G B Stark; H Bannasch; F Simunovic
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.